SUMOylation-driven nuclear translocation of HSF2BP alleviates MASLD via COX6A1-dependent mitochondrial reprogramming - PubMed
2 hours ago
- #MASLD
- #Mitochondrial Function
- #SUMOylation
- HSF2BP is upregulated in MASLD patient livers and HFD-fed mice, acting as a key metabolic regulator in hepatocytes.
- HSF2BP reduces hepatic lipid accumulation and improves glucose tolerance by enhancing mitochondrial function.
- SUMOylation of HSF2BP via UBC9 promotes its nuclear translocation, leading to upregulation of COX6A1 in mitochondrial complex IV.
- Impaired hepatic SUMOylation in MASLD disrupts HSF2BP's protective effects, while enhancing SUMOylation ameliorates liver steatosis.
- This pathway offers a promising therapeutic target for MASLD through mitochondrial reprogramming and lipid homeostasis regulation.